R2WA:F:F- (EUR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 0.428

Change

0.00 (-0.47)%

Market Cap

USD 0.37B

Volume

0.02M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZOE:F Zoetis Inc

N/A

USD 74.98B
MRK:F Merck & Company Inc

N/A

USD 67.63B
MRKC:F MERCK KGAA NAM.SP.ADR

N/A

USD 66.75B
TKD:F Takeda Pharmaceutical Company ..

N/A

USD 38.24B
TKDA:F Takeda Pharmaceutical Company ..

N/A

USD 37.78B
H6D:F Haleon PLC

N/A

USD 36.53B
H6D0:F Haleon PLC

N/A

USD 36.51B
TEV:F Teva Pharmaceutical Industries..

N/A

USD 17.71B
3KY:F HANSOH PHARMAC. HD-00001

N/A

USD 12.77B
NB3:F Neurocrine Biosciences Inc

N/A

USD 12.72B

ETFs Containing R2WA:F

EMFM Global X Next Emerging & .. 0.37 % 0.55 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.73% 43% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.73% 38% F 38% F
Trailing 12 Months  
Capital Gain 12.04% 64% D 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.04% 57% F 56% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.40% 59% D- 43% F
Dividend Return -1.40% 55% F 38% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.19% 96% N/A 91% A-
Risk Adjusted Return -19.46% 51% F 35% F
Market Capitalization 0.37B 60% D- 45% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.